Susquehanna Fundamental Investments LLC Makes New Investment in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

Susquehanna Fundamental Investments LLC bought a new stake in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 213,213 shares of the company’s stock, valued at approximately $1,002,000.

Several other hedge funds have also made changes to their positions in FULC. Barclays PLC raised its holdings in shares of Fulcrum Therapeutics by 367.1% in the third quarter. Barclays PLC now owns 124,141 shares of the company’s stock valued at $443,000 after acquiring an additional 97,565 shares in the last quarter. Geode Capital Management LLC increased its position in Fulcrum Therapeutics by 1.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,320,862 shares of the company’s stock valued at $4,716,000 after purchasing an additional 13,485 shares during the period. Matisse Capital raised its holdings in shares of Fulcrum Therapeutics by 20.4% in the 4th quarter. Matisse Capital now owns 128,445 shares of the company’s stock valued at $604,000 after purchasing an additional 21,728 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Fulcrum Therapeutics by 2.3% in the 4th quarter. Bank of New York Mellon Corp now owns 141,873 shares of the company’s stock valued at $667,000 after purchasing an additional 3,126 shares in the last quarter. Finally, Bailard Inc. purchased a new stake in shares of Fulcrum Therapeutics in the 4th quarter worth approximately $169,000. 89.83% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “neutral” rating and issued a $4.00 price objective on shares of Fulcrum Therapeutics in a research note on Wednesday, February 26th. One analyst has rated the stock with a sell rating, six have given a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $8.63.

Fulcrum Therapeutics Stock Up 13.8 %

Shares of FULC opened at $4.38 on Friday. The company has a 50 day moving average of $3.14 and a two-hundred day moving average of $3.62. The company has a market cap of $236.43 million, a price-to-earnings ratio of -14.13 and a beta of 2.13. Fulcrum Therapeutics, Inc. has a twelve month low of $2.32 and a twelve month high of $10.13.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its quarterly earnings data on Thursday, May 1st. The company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.01. On average, sell-side analysts expect that Fulcrum Therapeutics, Inc. will post -0.16 EPS for the current year.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.